ZA200210359B - Pharmaceutical compositions. - Google Patents

Pharmaceutical compositions.

Info

Publication number
ZA200210359B
ZA200210359B ZA200210359A ZA200210359A ZA200210359B ZA 200210359 B ZA200210359 B ZA 200210359B ZA 200210359 A ZA200210359 A ZA 200210359A ZA 200210359 A ZA200210359 A ZA 200210359A ZA 200210359 B ZA200210359 B ZA 200210359B
Authority
ZA
South Africa
Prior art keywords
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
ZA200210359A
Other languages
English (en)
Inventor
Ganter Sabina Maria
Wagner Robert Frank
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200210359B publication Critical patent/ZA200210359B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
ZA200210359A 2000-06-22 2002-12-20 Pharmaceutical compositions. ZA200210359B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59968700A 2000-06-22 2000-06-22

Publications (1)

Publication Number Publication Date
ZA200210359B true ZA200210359B (en) 2003-11-13

Family

ID=24400655

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200210359A ZA200210359B (en) 2000-06-22 2002-12-20 Pharmaceutical compositions.

Country Status (21)

Country Link
EP (2) EP1296677A2 (xx)
JP (3) JP2003535895A (xx)
KR (2) KR100659644B1 (xx)
CN (2) CN100450478C (xx)
AU (2) AU8576801A (xx)
BR (1) BR0111868A (xx)
CA (1) CA2411882C (xx)
CZ (1) CZ20024180A3 (xx)
EC (1) ECSP024389A (xx)
HK (2) HK1052868A1 (xx)
HU (1) HUP0301390A3 (xx)
IL (2) IL153428A0 (xx)
MX (1) MXPA02012683A (xx)
NO (1) NO20026123L (xx)
NZ (2) NZ540748A (xx)
PL (1) PL358290A1 (xx)
RU (1) RU2333757C2 (xx)
SG (1) SG162605A1 (xx)
SK (1) SK18062002A3 (xx)
WO (1) WO2001097805A2 (xx)
ZA (1) ZA200210359B (xx)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ293257B6 (cs) * 1998-12-23 2004-03-17 Novartis Ag Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
BRPI0306907B8 (pt) * 2002-01-17 2021-05-25 Novartis Ag composição farmacêutica, que compreende valsartan e inibidor de nep ou seus sais
US7468390B2 (en) 2002-01-17 2008-12-23 Novartis Ag Methods of treatment and pharmaceutical composition
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
TWI299663B (en) * 2002-05-14 2008-08-11 Novartis Ag Methods of treatment
KR100882156B1 (ko) * 2003-08-08 2009-02-06 아지노모토 가부시키가이샤 나테글리니드 함유 제제
WO2006021443A2 (en) * 2004-08-26 2006-03-02 Novartis Ag Composition comprising an at1 receptor blocker and a macrolide t-cell immunomodulator
SI2033629T1 (sl) 2004-12-24 2013-01-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Trden farmacevtski sestavek, ki obsega valsartan
JP2009001520A (ja) * 2007-06-21 2009-01-08 Kowa Co ジフェンヒドラミン含有固形製剤
RU2487710C2 (ru) 2007-10-09 2013-07-20 Новартис Аг Фармацевтическая композиция валсартана
WO2009059605A1 (en) * 2007-11-08 2009-05-14 University Of Copenhagen Small scale solid state screening
EP2067470A1 (en) * 2007-12-03 2009-06-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions containing valsartan and process for its preparation
WO2011102702A2 (en) 2010-02-16 2011-08-25 Krka, D. D., Novo Mesto Process for the preparation of oral solid dosage forms comprising valsartan
CN102362865B (zh) * 2011-10-28 2013-06-26 山东司邦得制药有限公司 一种含有盐酸贝尼地平和缬沙坦的复方制剂及其应用
WO2013098576A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan
WO2013098578A1 (en) 2011-12-31 2013-07-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Immediate release pharmaceutical composition of valsartan hydrochlorothiazide
CN103599084B (zh) * 2013-11-22 2018-10-30 威海迪素制药有限公司 一种降压组合物
CN112807286A (zh) * 2021-01-20 2021-05-18 海南皇隆制药股份有限公司 一种缬沙坦分散片制备方法和缬沙坦分散片
CN112826806A (zh) * 2021-01-20 2021-05-25 海南皇隆制药股份有限公司 一种缬沙坦片制备方法和缬沙坦片
EP4295839A1 (en) 2022-06-20 2023-12-27 KRKA, d.d., Novo mesto Combination of valsartan and indapamide

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122007000050I1 (de) 1990-02-19 2007-11-08 Novartis Ag Acylverbindungen
JPH09510225A (ja) * 1994-03-17 1997-10-14 チバ−ガイギー アクチェンゲゼルシャフト バルサルタンを用いる糖尿病性ネフロパシーの治療
BR9611007A (pt) * 1995-10-06 1999-07-13 Novartis Ag Antagonistas do receptor at1 para prevenir e tratar a deficiência renal pós-isquêmica e para a proteção de rins isquêmicos
DE69718146T2 (de) * 1996-02-29 2003-10-02 Novartis Ag At1 rezeptor antagonist zur anregung von apoptosis
EP0904060B1 (en) * 1996-05-20 2003-12-10 Janssen Pharmaceutica N.V. Antifungal compositions with improved bioavailability
GB9613470D0 (en) 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US6541669B1 (en) * 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
SE9802973D0 (sv) * 1998-09-03 1998-09-03 Astra Ab Immediate release tablet
CZ293257B6 (cs) * 1998-12-23 2004-03-17 Novartis Ag Farmaceutický přípravek obsahující antagonistu receptoru AT1 pro léčení nemocí spojených s nárůstem receptorů AT1 v subepiteliální vrstvě
PL365696A1 (en) * 2000-04-12 2005-01-10 Novartis Ag Combination of organic compounds

Also Published As

Publication number Publication date
MXPA02012683A (es) 2003-04-25
KR100659644B1 (ko) 2006-12-21
ECSP024389A (es) 2003-02-06
IL153428A (en) 2013-12-31
KR100525341B1 (ko) 2005-11-02
SK18062002A3 (sk) 2003-07-01
RU2333757C2 (ru) 2008-09-20
EP2072049A2 (en) 2009-06-24
CN1437469A (zh) 2003-08-20
AU8576801A (en) 2002-01-02
BR0111868A (pt) 2003-07-01
JP2003535895A (ja) 2003-12-02
KR20050085978A (ko) 2005-08-29
CN1221256C (zh) 2005-10-05
NO20026123D0 (no) 2002-12-19
WO2001097805A2 (en) 2001-12-27
CA2411882C (en) 2011-09-06
NZ540748A (en) 2007-04-27
PL358290A1 (en) 2004-08-09
CA2411882A1 (en) 2001-12-27
HUP0301390A3 (en) 2005-04-28
HK1083452A1 (en) 2006-07-07
IL153428A0 (en) 2003-07-06
JP2012211200A (ja) 2012-11-01
WO2001097805A3 (en) 2002-08-29
KR20030019450A (ko) 2003-03-06
CN1679551A (zh) 2005-10-12
HUP0301390A2 (hu) 2003-11-28
HK1052868A1 (zh) 2003-10-03
CZ20024180A3 (cs) 2003-04-16
NZ522953A (en) 2005-10-28
NO20026123L (no) 2003-02-18
JP2007091758A (ja) 2007-04-12
AU2001285768B2 (en) 2005-03-10
SG162605A1 (en) 2010-07-29
EP1296677A2 (en) 2003-04-02
CN100450478C (zh) 2009-01-14
EP2072049A3 (en) 2009-12-30

Similar Documents

Publication Publication Date Title
HK1036935A1 (en) Pharmaceutical compositions.
MXPA03000771A (es) Nuevas composiciones farmaceuticas.
HUP0300582A3 (en) Pharmaceutical compositions
AU6219601A (en) Pharmaceutical compositions
GB0009584D0 (en) Pharmaceutical compositions
ZA200101012B (en) Pharmaceutical combinations.
ZA200203486B (en) Novel pharmaceutical compositions.
ZA200210359B (en) Pharmaceutical compositions.
HUP0400553A3 (en) Pharmaceutical compositions
MXPA03002105A (es) Composiciones farmaceuticas.
GB0008485D0 (en) Pharmaceutical compositions
GB0009613D0 (en) Pharmaceutical compositions
ZA200110500B (en) Pharmaceutical composition.
GB0005382D0 (en) Pharmaceutical composition
MXPA03007318A (es) Composicion farmaceutica.
ZA200110501B (en) Pharmaceutical composition.
ZA200110499B (en) Pharmaceutical composition.
ZA200303911B (en) Medicinal compositions.
GB0002691D0 (en) Pharmaceutical composition
GB0000062D0 (en) Pharmaceutical compositions
GB0003929D0 (en) Pharmaceutical compositions
GB0008872D0 (en) Pharmaceutical compositions
HU0700204D0 (en) Pharmaceutical compositions
GB0031288D0 (en) Pharmaceutical compositions
GB0031282D0 (en) Pharmaceutical compositions